About Us

Xerion Limited is an Australian-based consumer healthcare company focused on revolutionizing standard of care in dermatology through the development and commercialization of innovative therapies and diagnostics.

The company’s product portfolio includes a robust pipeline of dermatological products already in the market (TGA listed anti-fungal products) and under development based on the proprietary bioactive ingredient AMYCOT®, which is derived from microalgae.

Xerion Limited also has the exclusive commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide, which has the ability to transform certain aspects of the personalised nutrition market. The technology allows simple, accessible, personalized determination of an individual’s fatty acid profile to help improve their health and achieve their wellness goals.  One application for this technology is its utility as a companion diagnostic tool for the high value consumer supplement market for which we have a distribution agreement with BASF, a large global player.

The company’s product portfolio includes proprietary algae bioactives and TGA approved anti-fungal products:

  • AMYCOT®: algal complex mix of bioactives with anti-fungal, anti-bacterial, anti-inflammatory and skin-repair properties.
  • KALM: Xerion’s lead product, a topical anti-fungal product line.
  • PUFAcoat: a proprietary dried blood spot (DBS) which stabilises fatty acids for long periods of time in ambient conditions facilitating the accurate measurement of fatty acids and is a useful tool in determining the Omega 3 Index.

Xerion has a robust product pipeline and research partnerships to extend its product range and indications.

Directors & Management

The Company has a highly experienced Board of Directors and Management comprising the following personnel:


Board Of Directors

Andrew Monk


Andrew is a seasoned Chairman of public corporations involving restructures, growth phase, mergers and acquisitions. He has extensive technical experience in standards setting and regulations across agrifood, health/wellness and cosmetics sectors. He has a BSc, PhD and is Adjunct Ass. Prof. at University of New England Armidale School of Law.

Peter Streader

Non-Executive Diorector

Peter has a legal background and is an experience company Director and Chairman. He has helped form, develop and manage a number of public and private domestic and international companies. Peter holds a Bachelor of Law from University of Melbourne and was a Fellow of the AICD for 18 years.

Tim Cushway

Non-Executive Director

Tim qualified with a Bachelor of Science and an experienced pharmaceutical professional with over 20 years in management, clinical development, medical affairs, regulatory, marketing and sales. Based in Singapore he is also experienced in working with multi-cultural teams

George Su

Non-Executive Director

Mr Su headed CITIC Securities Australian Operation between 2009 and 2013 with special focus on cross border transactions between Australia and China. Mr Su currently serves on ASX listed boards including Oriental Technology Investment Co Ltd and YPB Group.

Daniel P Goldman

Managing Director

Danny has extensive operational and financial expertise in a number of corporate segments. He has been CFO of a number of listed and private companies as well as spending time at Ernst & Young Chartered Accountants. Danny is a qualified Chartered Accountant and holds degrees in Accounting Science and Commerce.

Jeremy Keane

Non-Executive Director

Jeremy is an experienced NED and MD with extensive experience in the human services, healthcare pharmaceutical and medical device industries. He has demonstrated capability to rapidly and profitably grow healthcare organisations through both the execution of organic and M&A based growth strategies. He is a strong administrator skilled in business strategy development & execution, M&A and company directorship. He has a B. Physio, MBA and is a Graduate of the AICD.


Dr Leodevico (Vic) Ilag

Chief Scientific Officer

Vic has more than 20 years biotech experience serving in senior executive roles in leading biotech companies, in Australia, Europe and the USA. He has also co-founded a number of start-up companies. Vic has a PhD in Microbiology/Immunology and done postdoctoral studies in structural biology.

Sharyn Cunningham

Chief Finance Officer & Co-Company Secretary

Sharyn is an experienced Chartered Accountant with both large public and small company experience. She has previously worked with Shell Australia and Grant Thornton.

Jeanette Lodge

Chief Regulatory Officer

Jeanette has Masters in Medical Science and more than23 years of industry experience in regulatory affairs, medical writing and quality management systems. She has held positions in a global healthcare company and has effective working relationships with TGA and Medsafe.

Andres Monroy Cepeda

Head Of Manufacturing & Quality Assurance

Andres is an experienced pharmaceutical manufacturing and QA specialist with 15 years in operations, quality & compliance. His experience spans both private and public companies in the healthcare, pharmaceutical and medical device industries globally. Andres posesses a master of App.Sc. and an MBA.





Xerion’s first bioactive ingredient is AMYCOT®, an antimicrobial extract derived through a proprietary process from the microalgae Arthrospira maxima, that has a number of activities including:

  • anti-fungal (specific action against a major structural component of fungi cell walls)
  • anti-bacterial (against gram positive bacteria)
  • anti-viral (against Papilloma and Herpes simplex viruses)
  • anti-inflammatory
  • skin repair

AMYCOT® may therefore be regarded as a product platform and the first products to be commercialised are based primarily on AMYCOT®’s fungicidal activity under the brand Calmagen® with additional anti-inflammatory and skin repair benefits.

1. Manoj Parekh, Girisha Ramaiah, Prachi Pashilkar, Ranjani Ramanujam, Peter Johnston and Leodevico L. Ilag (2017) A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis. BMC Complementary and Alternative Medicine 17:464. DOI 10.1186/s12906-017-1970-2

2. Ilag LL (2018) Leodevico L Ilag (2018) Ringworm Disease – Causes, Diagnosis and Treatment: AMYCOT®, a Novel Natural Treatment for Ringworm and other Tinea Infections. Journal of Dermatology and Clinical Research 6(1):1114


Xerion has acquired the exclusive license in Australia and a number of other countries to the PUFAcoat technology from world leading lipids and nutrition researcher Prof Robert Gibson of the FOODplus Research Centre at the University of Adelaide.

The PUFAcoat protection system comprises a combination of protectants on a defined collection matrix. PUFAcoat can protect against the oxidation of long chain polyunsaturated fatty acids (LCPUFA) in blood spots at ambient temperature for at least 2 months. PUFAcoat was found to prevent any significant loss in the level of the two most important omega 3 fatty acids, EPA and DHA, in blood spots following up to 2 months of storage at room temperature.

1. Ge Liu, Beverly Sara Mühlhäusler, Robert Alan Gibson (2014) A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application. Prostaglandins, Leukotrienes and Essential Fatty Acids 91:251–260. 

2. Ge Liu, Beverly Sara Mühlhäusler, and Robert Alan Gibson (2015) a target="_blank" href="">Evaluation of contamination associated with current blood spot technology for determining the fatty acid status of individuals. European Journal of Lipid Science and Technology 117(8):1280-1286.

3. Erandi Hewawasam, Ge Liu, David W. Jeffery, Beverly Sara Mühlhäusler, Robert A. Gibson (2017) A validated method for analyzing polyunsaturated free fatty acids from dried blood spots using LC–MS/MS. Prostaglandins, Leukotrienes and Essential Fatty Acids 125:1-7.

4. Carmel T Collins et al (2017) Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants. New England Journal of Medicine 376:1245-1255. DOI:!10.1056/NEJMoa1611942

5. Erandi Hewawasam, Ge Liu, David W. Jeffery, Robert A. Gibson, and Beverly S Mühlhäusler (2018) Estimation of the Volume of Blood in a Small Disc Punched From a Dried Blood Spot Card. European Journal of Lipid Science and Technology 120(3): 1700361(1-6).

6. Chang Gao, Robert A Gibson, Andrew J McPhee, Shao J Zhou, Carmel T Collins, Maria Makrides, Jacqueline Miller, Ge Liu. (2018) Comparison of breast milk fatty acid composition from mothers of premature infants of three countries using novel dried milk spot technology. Prostaglandins Leukot Essent Fatty Acids. 139:3-8. doi: 10.1016/j.plefa.2018.08.003

7. Maximus Berger, Sean Taylor, Linton Harriss, Sandra Campbell, Fintan Thompson, Samuel Jones, Maria Makrides, Robert Gibson, G. Paul Amminger, Zoltan Sarnyai and Robyn McDermott (2018) Cross-sectional association of seafood consumption, polyunsaturated fatty acids and depressive symptoms in two Torres Strait communities, Nutritional Neuroscience 3:1-10 DOI: 10.1080/1028415X.2018.1504429

5. Ryo Okubo, Hiroko Noguchi, Kei Hamazaki, Masayuki Sekiguchi, Takayuki Kinoshita, Noriko Katsumata, Tomomi Narisawa, Yasuhito Uezono, Jinzhong Xiao, Yutaka J. Matsuoka (2018) Association between blood polyunsaturated fatty acid levels and depressive symptoms in breast cancer survivors. Prostaglandins Leukot Essent Fatty Acids.  139:9-13. doi: 10.1016/j.plefa.2018.11.002.

9. Ryo Okubo, Hiroko Noguchi, Kei Hamazaki, Masayuki Sekiguchi, Takayuki Kinoshita, Noriko Katsumata, Tomomi Narisawa, Yasuhito Uezono, Jinzhong Xiao, Yutaka J. Matsuoka (2019) Fear of cancer recurrence among breast cancer survivors could be controlled by prudent dietary modification with polyunsaturated fatty acids. Journal of Affective Disorders 245:1114–1118, doi: 10.1016/j.jad.2018.12.014

Bioactive New Product Development (NPD) Platform

Xerion’s Bioactive NPD platform integrates different generic and proprietary technologies from the discovery of bioactives through clinical validation up to a new marketable product.

In addition to Xerion’s existing product range within the marketplace, the Company will be developing new product initiatives that aim to improve the quality of life of people, world-wide.

1. Leodevico L Ilag (2018) Botanicals and its extracts: A new drug discovery and development paradigm for chronic and age-related illnesses. Med Res Innov 2(1): 1-3. doi: 10.15761/MRI.1000131

2. Leodevico L Ilag (2018) Are Long-Chain Polyunsaturated Fatty Acids the Link between the Immune System and the Microbiome towards Modulating Cancer? Medicines 5(3):102.
Product Pipeline

Dermatology Product Pipeline

AMYCOT® is the basis for the different dermatological products under development including the KALM range of anti-fungal products comprises: a cream, lotion and powder all of which are Listed Medicines with the Australian TGA

PUFAcoat Dried Blood Spot Technology

Revolutionary precision dried blood spot technology that accurately measures fatty acids in blood and other biological fluids.


Xerion Limited is an Australian public unlisted specialty pharmaceutical company focused on the commercialisation of two personalised medicine products in the over-the-counter (OTC) pharmaceutical and pathology markets. Xerion has great financial prospects, and immense upside potential through launching its current range in key international markets, and a pipeline of new product development.

Xerion has two proprietary technology platforms with products commercialised from each in the global OTC and personalised medicine markets:

  • KALM: a range of OTC dermaceutical products featuring a key anti-fungicidal ingredient, AMYCOT®. nailKALM® is Xerion’s flagship product.
  • PUFA: dried blood spot (DBS) test kits for consumers and healthcare professionals to test fatty acid levels, including omega-3 levels.

Key Company Highlights

  • Leading brand (nailKALM®) with strong IP protection through internationally granted patents and recently ranged in all Chemist Warehouse stores.
  • Very high product efficacy with TGA approval secured to treat fungal infections.
  • Competitive advantage with natural active ingredient and zero toxicity.
  • Clearly differentiated from the competition through ease of use (no filing necessary) and efficacy.
  • Clear path to take AMYCOT® to the US as a prescription nail fungal drug.
  • Clinical trial for a new acne treatment is underway in Israel.
  • Large global markets including nail fungus (US$3.4bn), acne (US$4.7bn) and atopic dermatitis (US$7.0bn+). 

Xerion Ltd Summary Note (October 2019)[1]



HEAD OFFICE ADDRESS: 246 Esplanade Brighton VIC 3186 Australia
HEAD OFFICE PHONE: + 61 3 9553 8896